Psilocybin, a psychedelic compound, was generally well-tolerated and reduced obsessive-compulsive disorder (OCD) symptoms in a small clinical trial. No serious adverse events, psychotic symptoms, or changes in suicide severity occurred. Psilocybin, but not placebo, significantly lowered scores on the Yale-Brown Obsessive Compulsive Scale. After eight weeks of treatment including at least four high doses, 73.3% of participants responded (at least 35% reduction in symptoms), and 40% achieved remission. Benefits diminished but remained substantial at six months. Higher cumulative doses were linked to greater symptom reduction. Larger trials are needed to confirm efficacy and refine protocols.
Inhibiting the posterior cingulate cortex with transcranial focused ultrasound during a ten-day silent retreat enhanced meditative qualities such as equanimity, concentration, and sensory clarity. Twenty-eight meditators received two stimulation sessions and reported significant increases in trait mindfulness, nondual awareness, and interoceptive body listening. Qualitative reports showed consistent differences between stimulation and non-stimulation days, including shifts in self-perception and cathartic emotional release. The effects often interacted with participants' ongoing psychological challenges, suggesting tFUS may increase baseline equanimity and support meditative development. Implementation was feasible but required logistical planning; limitations include the quasi-experimental design and reliance on self-reports.